Webb31 mars 2024 · Under the agreement, Scynexis will receive an upfront payment of $90 million from GSK. SCYX will be entitled to $245.5 million for development, regulatory and … WebbFör 1 dag sedan · JERSEY CITY, N.J., April 13, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to …

SCYNEXIS wins FDA label expansion for anti-fungal therapy

Webb30 mars 2024 · GSK plc and Scynexis Inc have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets).; The FDA approved the antifungal for … Webb7 dec. 2024 · These risks and uncertainties include, but are not limited, to: risks inherent in the regulatory process to obtain FDA approval for ibrexafungerp; SCYNEXIS’s need for … calgary scuba stores

GSK and SCYNEXIS announce an exclusive agreement to …

Webb11 apr. 2024 · SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly... Webb30 mars 2024 · The upfront will lock in an exclusive license to Scynexis’ Brexafemme, which was approved in 2024 to treat a yeast infection known as vulvovaginal … WebbJERSEY CITY, N.J., April 13, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES … coach leash and collar